
ADAPT+ study evaluates efgartigimod's long-term safety, tolerability, and efficacy in adults with generalized myasthenia gravis (gMG). In this open-label, single-arm extension of the pivotal phase 3 ADAPT study, participants received up to 17 treatment cycles over 548 days. Most experienced treatment-emergent adverse events, with headache and COVID-19 being prominent. Clinically meaningful improvements were observed in Myasthenia Gravis-Activities of Daily Living and Quantitative Myasthenia Gravis scores. The results affirm efgartigimod's significant clinical benefits, supporting its extended use with an individualized dosing approach for gMG treatment.
Like
Save
Share